Wells Fargo raises Abbvie stock price target on HS drug potential
Wells Fargo raises Abbvie stock price target on HS drug potential Investing.com
Covered in this story
What has happened since
- AbbVie is up 6.9% since this was published, 50 days ago.
- Wells Fargo is down 6.9% since this was published, 50 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
Wells Fargo’s $300 target on $ABBV is on the record and being tracked to Aug 2027 (12-month default), scored on the close that day.
Wells Fargo’s track record →Analyst targets on AbbVie
- Bank of America: $262 → $289 by Sep 2027 · Buy via AOL.com
- Guggenheim: $244 → $288 by Aug 2027 · Buy via GuruFocus
- Canaccord Genuity: $245 → $290 by Aug 2027 via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABBV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on AbbVie →Dalsna Finance is currently tracking 48 stories mentioning AbbVie, the earliest published 29 Apr 2026.
Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.